Education
- Temple University Beasley School of Law, J.D., magna cum laude, 2012, Order of the Coif
- Harvard University, Ph.D., 2000, organic chemistry
- University of Pennsylvania, B.A., cum laude, 1993, chemistry
Bar Admissions
- Pennsylvania
- U.S. Patent and Trademark Office
- Podcast, “New Developments in Obviousness-Type Double Patenting and Original Patent Requirements,” Patents: Post-Grant Podcast, August 12, 2024.
- Co-author, “Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia,” Journal of Pharmacology and Experimental Therapeutics, 2017.
- Co-author, “Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295,” ACS Medicinal Chemistry Letters, 2010.
- Co-author, “Substituted Benzothiadizine Inhibitors of Hepatitis C Virus Polymerase,” Bioorganic & Medicinal Chemistry Letters, 2009.
- Co-author, “Synthesis and Biological Activity of Heteroaryl 3-(1,1-dioxo-2H-(1,2,4)-benzothiadizin-3-yl)-4-hydroxy-2(1H)-quinolinone Derivatives as Hepatitis C Virus NS5B Polymerase Inhibitors,” Bioorganic & Medicinal Chemistry Letters, 2009.
- Co-author, “3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, Potent Inhibitors of Hepatitis C Virus RNA-dependent RNA Polymerase,” Journal of Medicinal Chemistry, 2006.
- Co-author, “A Highly Efficient, Asymmetric Synthesis of Benzothiadiazine-Substituted Tetramic Acids: Potent Inhibitors of Hepatitis C Virus RNA-dependent RNA Polymerase,” Organic Letters, 2006.
- Quoted, “GSK Exec Joins Troutman Pepper’s Life Sciences IP Team,” Law360, February 14, 2024.